Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.7452W HIGH $6.60
Volume
1.60 M
Value Traded
9.31 M
Short % Float
14.47%
-11.16%Week
-29.86%1 Month
-30.11%3 Month
-3.47%6 Month
-80.08%5 Year
-62.14%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
547.41 M
EPS (TTM)
-0.51
P/E Ratio
-
Ent. Value
376.09 M
Total Shares
139.82 M
Float Shares
111.06 M
Insiders
24.55%
Institutions
68.40%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
ACRS Catalyst Timeline
Dated clinical, regulatory and corporate events for Aclaris Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Aclaris Therapeutics, Inc.
602Total events
11Upcoming
146Tier-1 (high impact)
2015 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Fast Track DesignationATI-2138Designation
FDA grants Fast Track Designation for modzatinib (ATI-2138) for moderate to severe lichen planus
moderate to severe lichen planus (LP) including oral erosive LP, cutaneous LP, and lichen planopilarissource ↗
▲Full ResultsATI-052Clinical Data
Positive full top line results from Phase 1a SAD/MAD trial of ATI-052
healthy volunteerssource ↗
▲Enrollment CompleteATI-045Trial
Enrollment completed in Phase 2 trial of bosakitug in atopic dermatitis
atopic dermatitissource ↗
▲Oral PresentationATI-9494Presentation
Preclinical data on ATI-9494 presented at FASEB Immunoreceptors and Immunotherapy conference
immuno-inflammatory diseasessource ↗
▼ATM ProgramCorporate
Sold 7.3 million shares under ATM agreement for $40.2 million gross proceeds
◆Topline ReadoutATI-052Clinical Data
Topline results expected from Phase 1b atopic dermatitis trial
atopic dermatitissource ↗
◆Trial InitiationATI-2138Trial
Initiate Phase 2b trial for ATI-2138 in Lichen Planus
Lichen Planussource ↗
◆Trial InitiationATI-052Trial
Phase 2b program initiation expected
asthma and atopic dermatitissource ↗
◆Oral PresentationPresentation
Aclaris Therapeutics to participate in fireside chat at 2026 Jefferies Global Healthcare Conference
◆Oral PresentationPresentation
Corporate presentation at 2026 Bank of America Healthcare Conference
▲Full ResultsATI-052Clinical Data
Full top line results from Phase 1a SAD/MAD trial of ATI-052
healthy volunteerssource ↗
▲Full ResultsATI-052Clinical Data
Positive full top line results from Phase 1a SAD/MAD trial of ATI-052
Healthy Volunteerssource ↗
◆Pipeline PrioritizationATI-2138Corporate
Lead indication selection for ATI-2138
immuno-inflammatory diseasessource ↗
●Oral PresentationPresentation
Management conference call to discuss ATI-052 results and ATI-2138 program
◆Enrollment UpdateATI-052Trial
Enrollment ongoing in Phase 1b atopic dermatitis trial
Atopic Dermatitissource ↗
◆Oral PresentationPresentation
Fireside chat at H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
◆Topline ReadoutATI-052Clinical Data
Top line results expected from Phase 1b atopic dermatitis trial
Atopic Dermatitissource ↗
◆Topline ReadoutATI-045Clinical Data
Top line results expected from Phase 2 trial
moderate-to-severe atopic dermatitissource ↗
▲Poster PresentationATI-2138Presentation
ePoster presentation at 2026 AAD Annual Meeting
Moderate-to-Severe Atopic Dermatitissource ↗
◆Poster PresentationATI-2138Presentation
ePoster on results from Phase 2a trial of ATI-2138 at 2026 AAD Annual Meeting
moderate-to-severe atopic dermatitissource ↗
▲Enrollment CompleteATI-045Trial
Completed patient enrollment in Phase 2 trial of bosakitug in atopic dermatitis
moderate-to-severe atopic dermatitissource ↗
◆Oral PresentationPresentation
Aclaris Therapeutics to participate in fireside chat at Leerink Partners 2026 Global Healthcare Conference
◆Management ChangeCorporate
Joe Monahan to retire as CSO, transition to Special Scientific Advisor through Q1 2026
▲Interim AnalysisATI-052Trial
Positive interim results from Phase 1a SAD/MAD trial of ATI-052
healthy volunteerssource ↗
▲Preclinical PoCATI-2138Preclinical
ATI-2138 demonstrated potential best-in-class hair regrowth in murine alopecia model
alopeciasource ↗
▲Preclinical PoCATI-2138Preclinical
Positive preclinical results in murine model of severe alopecia areata
alopecia areatasource ↗
▲Trial InitiationATI-052Trial
Initiated Phase 1b proof-of-concept trial in atopic dermatitis
atopic dermatitissource ↗
▲Trial CompletionATI-2138Trial
Phase 2a trial in atopic dermatitis completed
atopic dermatitissource ↗
▲Interim AnalysisATI-052Trial
Positive interim results from Phase 1a SAD/MAD trial of ATI-052
healthy adultssource ↗
◆Trial InitiationATI-052Trial
Initiation of Phase 1b POC trial in atopic dermatitis expected imminently
atopic dermatitissource ↗
◆Trial InitiationATI-2138Trial
Expected initiation of Phase 2b trial in alopecias
alopecia areatasource ↗
▲Trial InitiationATI-052Trial
Initiated Phase 1b proof-of-concept trial in atopic dermatitis
atopic dermatitissource ↗
Past FDA Catalysts and PDUFA Decisions
How ACRS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-09-17 | ATI-2138 (oral covalent inhibitor of ITK and JAK3) | Phase 2a data readout | Phase 2a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C48 / 100
Pipeline Score
$661M
Pipeline Value
Fair Value
Valuation Signal
6
Drugs Scored
1.3x
rNPV / MCap
Top 21%
Micro Cap(rank 139 of 658)
Percentile Rank
Aclaris Therapeutics, Inc. carries a moderate pipeline score (48/100), with $2.5B risk-adjusted pipeline value, led by ATI-045 in Atopic Dermatitis (Phase 2), across $57B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ATI-045 Small moleculeNCT07011706 | Atopic Dermatitis | Phase 2 | ACTIVE NOT_RECRUITING | 110 | Nov 24, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every ACRS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ATI-052 | Phase 1a | 2026-05-07 | The Phase 1a SAD/MAD trial of ATI-052 demonstrated a best-in-class pharmacokinetic/pharmacodynamic profile with an extended dosing schedule of up to every three months, exceeding Aclaris' target profile for the drug's efficacy.Read More | Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update - Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Exceed Aclaris' Target Profile, Validating PotenRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kolbeck Roland WilhelmOfficer (Chief Scientific Officer) | Option | 36,375 36,375 held | $0.00 | 08/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ACRS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 0.6 % (100 %) | 67.30 M | 12.72 M | 86.99% ( 5.92 M) |
ACRS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ACRS ranks across every disease it competes in
Competitive Position is a premium feature
See how ACRS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialACRS News
ACRSAclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
Aclaris Therapeutics will participate in the 2026 Cantor Global Healthcare Conference on September 10, 2026. CEO Dr. Neal Walker will engage in a fireside chat during the event. A live and archived webcast will be available on Aclaris' website for at least 30 days, allowing broader access to the discussion.
Read more →ACRSAclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)
Aclaris Therapeutics has received Fast Track Designation from the FDA for modzatinib (ATI-2138) to treat moderate to severe lichen planus. This designation aims to expedite the drug's development and review process. Aclaris plans to begin a Phase 2b trial in the fourth quarter of 2026, highlighting the urgency of addressing this serious condition.
Read more →ACRSAclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update
Aclaris Therapeutics reported its second quarter 2026 financial results, highlighting positive outcomes from its Phase 1a trial of ATI-052 and reaffirming timelines for upcoming Phase 1b and Phase 2 trials. The company expects significant clinical data readouts in the latter half of 2026 and has a strong cash position to support its pipeline through 2028. However, the company also reported an increase in net loss compared to the previous year.
Read more →ACRSAclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Aclaris Therapeutics will participate in the 2026 Jefferies Global Healthcare Conference on June 4, 2026. CEO Dr. Neal Walker and the senior leadership team will engage in a fireside chat. The event will be accessible via a live and archived webcast on Aclaris' website for at least 30 days.
Read more →ACRSAclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) will participate in the 2026 Bank of America Healthcare Conference held on May 14, 2026. Dr. Hugh Davis, the President and COO, is scheduled to present at 9:35 AM PT. The event will be accessible via a live and archived webcast on the Aclaris website for at least 30 days following the conference. Aclaris focuses on developing treatments for immuno-inflammatory diseases, which are often inadequately addressed by current options.
Read more →ACRSAclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update
Aclaris Therapeutics reported its financial results for Q1 2026, highlighting progress in its clinical trials and corporate developments. The company announced successful results from its Phase 1a SAD/MAD trial for ATI-052, which exceeded expectations and reinforced its potential as a best-in-class treatment. Financially, Aclaris experienced a net loss of $19.8 million while generating $2.0 million in total revenue, primarily due to increased royalties. Additionally, the company has a solid cash position projected to support its operational needs through 2028.
Read more →ACRSAclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor
Aclaris Therapeutics announced positive results from its Phase 1a trial of ATI-052, a bispecific antibody targeting TSLP and IL-4Rα, indicating a strong safety and efficacy profile. The company also selected lichen planus as the lead indication for ATI-2138, an oral ITK/JAK3 inhibitor. Future studies for both compounds are planned, with results expected in the coming years.
Read more →ACRSAclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026
Aclaris Therapeutics will present results from its Phase 1a trial of ATI-052 and the lead indication selection for ATI-2138 on April 28, 2026. The announcement will precede a conference call and webcast scheduled for 8:30 AM EST. This update highlights Aclaris' commitment to developing treatments for immuno-inflammatory diseases.
Read more →ACRSClinical Pipeline Update: ATI-052: Full SAD MAD Results ATI-2138: Potential Mechanistically Complete Therapy for Lichen Planus
ATI-052 has shown promising results in recent clinical trials, demonstrating significant potency compared to existing treatments for conditions like atopic dermatitis and asthma. The drug exhibits a favorable pharmacokinetic and pharmacodynamic profile, allowing for sustained inhibition of key inflammatory mediators. Furthermore, a positive safety profile with minimal adverse events has been observed, supporting the continuation of clinical development. Future trials for ATI-052 are planned, aiming to establish its efficacy and safety in broader patient populations.
Read more →ACRS▲ +5.3%on this news
Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
Aclaris Therapeutics, Inc. will participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference on April 14, 2026, at 12:00 PM EDT. The event will feature CEO Dr. Neal Walker and senior leadership discussing the company's initiatives and research. A live webcast of the conference will be available on Aclaris' website, along with an archived version accessible for at least 30 days. This participation highlights Aclaris' commitment to addressing treatment gaps in immuno-inflammatory diseases.
Read more →ACRSResults Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138
Aclaris Therapeutics presented positive results from its Phase 2a trial of ATI-2138 at the 2026 AAD Annual Meeting. The trial showed significant improvements in disease severity, itch, and quality of life for patients with moderate-to-severe atopic dermatitis. ATI-2138, a selective oral inhibitor, was well tolerated and demonstrated a strong mechanistic rationale for its use in immuno-inflammatory diseases.
Read more →ACRSAclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Aclaris Therapeutics announced that an ePoster detailing results from its Phase 2a trial of ATI-2138 will be available at the 2026 American Academy of Dermatology Annual Meeting. The trial focuses on patients with moderate-to-severe atopic dermatitis and showcases data that has not been previously reported. ATI-2138 is a potent investigational oral covalent inhibitor targeting interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3). Aclaris aims to address the needs of patients who lack satisfactory treatment options for immuno-inflammatory diseases.
Read more →ACRS▼ -5.7%on this newsshared move
Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
Aclaris Therapeutics has successfully completed patient enrollment in its Phase 2 trial of bosakitug (ATI-045) for moderate-to-severe atopic dermatitis. The trial is randomized, double-blind, and placebo-controlled, aiming to evaluate the drug's efficacy and safety in 109 participants. Top-line results are anticipated in the fourth quarter of 2026. Bosakitug targets the thymic stromal lymphopoietin (TSLP) pathway, which is significant in managing inflammatory responses in atopic dermatitis.
Read more →ACRSAclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference
Aclaris Therapeutics will participate in the Leerink Partners 2026 Global Healthcare Conference on March 10, 2026. CEO Dr. Neal Walker and the senior leadership team will engage in a fireside chat. The event will be webcast live and archived on Aclaris' website for at least 30 days, promoting their focus on immuno-inflammatory diseases.
Read more →ACRS▼ -5.4%on this newsshared move
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Aclaris Therapeutics reported its financial results for Q4 and full year 2025, highlighting strong execution in its pipeline. The company announced positive interim results for ATI-052 and initiated two Phase 1b trials. Despite a decrease in revenue, Aclaris maintains a solid cash position, expected to fund operations into 2028, with several key milestones anticipated in 2026.
Read more →ACRSAclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052
Aclaris Therapeutics has launched a Phase 1b proof-of-concept trial for ATI-052, a bispecific antibody targeting asthma. This follows positive interim results from a previous trial in atopic dermatitis. The trial will assess safety and efficacy in approximately 16 patients, with top-line results expected in late 2026. Aclaris plans to initiate a Phase 2b program for both conditions thereafter.
Read more →ACRSAclaris Therapeutics to Participate in Two February Healthcare Conferences
Aclaris Therapeutics, Inc. announced its participation in two healthcare conferences in February 2026. The events will feature live and archived webcasts accessible on their website for at least 30 days. Aclaris is dedicated to developing innovative treatments for patients with immuno-inflammatory diseases.
Read more →ACRSAclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)
Aclaris Therapeutics announced positive preclinical results for its ITK/JAK3 inhibitor, ATI-2138, showing rapid and sustained hair regrowth in a murine model of severe alopecia areata. The study, conducted by Dr. Angela Christiano, indicated that ATI-2138 outperformed ritlecitinib. The company plans to initiate a Phase 2b trial in the first half of 2026.
Read more →ACRSCorporate Overview January 2026 EMPOWERING PATIENTS THROUGH THERAPEUTIC INNOVATION 2 Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that t
ACRS is advancing its therapy ATI-2138, which has shown promising clinical results in the treatment of immuno-inflammatory diseases such as atopic dermatitis. The therapy demonstrated significant reductions in inflammation and improved patient outcomes during Phase 2a trials. A robust pipeline is in place with additional studies set to begin in 2026, including indications for conditions like alopecia and asthma. ACRS's financial strength and commitment to innovation further support its potential in the biopharma sector.
Read more →About Aclaris Therapeutics, Inc.
Headquarters701 LEE ROAD, WAYNE, PA, 19087
Founded2012
BIOPHARMAWATCH ELITE PLUS
Trade the next ACRS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime